Balasa Dinverno & Foltz LLC Moderna, Inc. Transaction History
Balasa Dinverno & Foltz LLC
- $1.58 Billion
- Q3 2022
A detailed history of Balasa Dinverno & Foltz LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Balasa Dinverno & Foltz LLC holds 3,288 shares of MRNA stock, worth $381,243. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,288
Previous 3,225
1.95%
Holding current value
$381,243
Previous $461,000
15.62%
% of portfolio
0.02%
Previous 0.03%
Shares
5 transactions
Others Institutions Holding MRNA
# of Institutions
1,038Shares Held
245MCall Options Held
12.1MPut Options Held
9.36M-
Baillie Gifford & CO44.7MShares$5.18 Billion3.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA39MShares$4.53 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY25.4MShares$2.94 Billion0.06% of portfolio
-
State Street Corp Boston, MA14.5MShares$1.68 Billion0.07% of portfolio
-
Flagship Pioneering Inc. Cambridge, MA9.67MShares$1.12 Billion67.87% of portfolio
About Moderna, Inc.
- Ticker MRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 391,200,000
- Market Cap $45.4B
- Description
- Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...